Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature. Issue 1 (22nd November 2018)

• Record Type: Journal Article
• Authors: Erhart, Friedrich; Blauensteiner, Bernadette; Zirkovits, Gabriel; Printz, Dieter; Soukup, Klara; Klingenbrunner, Simone; Fischhuber, Katrin; Reitermaier, René; Halfmann, Angela; Lötsch, Daniela; Spiegl‐Kreinecker, Sabine; Berger, Walter; Visus, Carmen; Dohnal, Alexander
• Is Part Of: Journal of cellular and molecular medicine. Volume 23:Issue 1(2019)
• Page Start: 281
• Page End: 292
• Publication Date: 2018-11-22
• Subjects: flow cytometry -- glioblastoma -- gliomaspheres -- molecular signature -- multi‐color staining -- stem‐like cell -- viSNE; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13927
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Glioblastoma is the most dangerous brain cancer. One reason for glioblastoma's aggressiveness are glioblastoma stem‐like cells. To target them, a number of markers have been proposed (CD133, CD44, CD15, A2B5, CD36, CXCR4, IL6R, L1CAM, and ITGA6). A comprehensive study of co‐expression patterns of them has, however, not been performed so far. Here, we mapped the multidimensional co‐expression profile of these stemness‐associated molecules. Gliomaspheres – an established model of glioblastoma stem‐like cells – were used. Seven different gliomasphere systems were subjected to multicolor flow cytometry measuring the nine markers CD133, CD44, CD15, A2B5, CD36, CXCR4, IL6R, L1CAM, and ITGA6 all simultaneously based on a novel 9‐marker multicolor panel developed for this study. The viSNE dimensionality reduction algorithm was applied for analysis. All gliomaspheres were found to express at least five different glioblastoma stem‐like cell markers. Multi‐dimensional analysis showed that all studied gliomaspheres consistently harbored a cell population positive for the molecular signature CD44+/CD133+/ITGA6+/CD36+. Glioblastoma patients with an enrichment of this combination had a significantly worse survival outcome when analyzing the two largest available The Cancer Genome Atlas datasets (MIT/Harvard Affymetrix: P = 0.0015, University of North Carolina Agilent: P = 0.0322). In sum, we detected a previously unknown marker combination – demonstrating feasibility, usefulness, and importance of high‐dimensional gliomasphere marker combinatorics.